尼妥珠单抗联合其他方法治疗晚期非小细胞肺癌的有效性及安全性meta分析  

Meta-analysis of the safety and efficacy of nimotuzumab combined with other therapies in the treatment of advanced non-small cell lung cancer

作　　者：邓滋敬 李华燕 王莉[1] 曾洁[1] DENG Zijing;LI Huayan;WANG Li;ZENG Jie(Department of Pharmacy,the Fifth Affiliated Hospital of Guangzhou Medical University,Guangzhou 510700,China;Department of Pharmacy,Foshan Women and Children Hospital,Foshan 528200,China;Department of Pharmacy,Zengcheng Branch of Nangfang Hospital,Guangzhou 511300,China)

机构地区：[1]广州医科大学附属第五医院药学部,广州510700 [2]佛山市南海区妇幼保健院药学部,佛山528200 [3]南方医院增城分院药学部,广州511300

出　　处：《上海医药》2023年第19期71-78,共8页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:系统评价尼妥珠单抗联合治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的疗效及安全性。方法:检索CNKI、万方、维普等数据库,收集尼妥珠单抗治疗晚期NSCLC的临床研究和包括有效性和安全性的结局指标。采用RevMan 5.3联合STATA 17软件进行meta分析。结果:共纳入20项临床研究,1631例患者。meta分析结果显示,与对照组相比,试验组的客观缓解率、疾病控制率都显著提高(P<0.001)。试验组中EGFR胞内信号通路分子mRNA含量较对照组降低(P<0.001)。两组患者中位无进展生存期(median progression-free survival,mPFS)、中位总生存期(median overall survival,mOS)、不良反应发生率比较,差异无统计学意义(P>0.05)。结论:尼妥珠单抗联合治疗能显著提高晚期NSCLC患者的临床疗效,但不能延长mOS、mPFS;尼妥珠单抗联合治疗安全性良好。Objective:To systematically evaluate the efficacy and safety of nimotuzumab combined with other therapies in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:Clinical studies on the combined use of nimotuzumab for the treatment of advanced NSCLC and outcomes including efficacy and safety were collected by searching CNKI,Wanfang,VIP and other databases and meta-analysis was performed using RevMan 5.3 and Stata 17.0 software.Results:A total of 20 clinical studies involving 1631 patients were included.Meta-analysis showed that objective response rate(ORR)and disease control rate(DCR)of the trial group were significantly higher than those of the control group(P<0.001).The mRNA contents of EGFR intracellular signaling pathway molecules in the trial group were lower than those in the control group(P<0.001).There were no significant differences in median progression-free survival(mOS)and median overall survival(mPFS)and the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Nimotuzumab combination treatment has good efficacy and safety in patients with advanced NSCLC,but can not extend mOS and mPFS.

关 键 词：尼妥珠单抗 META 分析 非小细胞肺癌 

分 类 号：R979.19[医药卫生—药品] R734.2[医药卫生—药学]